Pakistan continues to be dealing with a polio outbreak as four fresh cases have emerged, pushing the national tally to 37 this year, according to health officials on October 19, 2024. Health officials said that the regional reference laboratory for polio eradication at the National Institute of Health in Islamabad confirmed wild poliovirus type-1 (WPV1) in two children-one from each Balochistan and Khyber-Pakhtunkhwa.

In recent cases, a girl has been affected from Pishin, and two boys from Chaman and Noshki of Balochistan, and a girl from Lakki Marwat in KP. These are the first detections of the virus within Noshki and Lakki Marwat this year; isolated cases of poliovirus were previously reported within Chaman and Pishin. The province of Balochistan was the worst hit with 20 cases, Sindh had 10, Khyber Pakhtunkhwa had five, and Punjab and Islamabad had one case each.

A gigantic fight against polio has been on going in Pakistan- especially in Balochistan and southern KP-over the last two years. Immunisation campaigns have often been suspended or delayed because of local protests, insecurity, and community boycotts. Consequently, quite a number of children did not get the necessary vaccinations, making existing patches of vulnerability for the virus to flow within those pockets.

Noshki, located near Afghanistan's border, and Lakki Marwat have also recently reported some positive environmental samples that confirm the virus is present here, said a local reference laboratory official. Samples of latest cases are currently under genetic sequencing for checking spread of virus and origin.

As the threat of polio continues to grow, Pakistan has vowed to mount a nationwide campaign against it beginning from October 28. With the zeal to tackle the menace in the most effective manner, over 45 million children under the age of five will be vaccinated across the country.

Today, Afghanistan and Pakistan remain one of the few countries where polio has not yet been eradicated. The WHO said the virus remains a potential serious public health threat in areas with low vaccination coverage and weak surveillance.

India On Alert Against Polio

The country declared itself polio-free since 2014 and has kept the disease on bay almost a decade with very robust vaccination programs; however, two cases of vaccine-derived poliovirus cases reported in recent days from Meghalaya create some amount of doubts over a possible resurgence. Experts observe that in India, despite these detections taking place, strong coverage of vaccination at 90-95% and mandatory surveillance measures keep the risk of this widespread outbreak at bay.

The experts point out, however, that such stable situation in India requires continued surveillance. "Countries like Pakistan and parts of Africa remain at a high risk because vaccination rates in those areas are much lower," Dr. Siddharth, public health expert, said. Vaccination is an indispensable act in order to avoid the spread of this incapacitating disease that manifests most importantly as a nervous system affliction leading to the paralysis of a long period.

With concerted efforts from health authorities, there is hope someday that the scourge of polio will be completely eradicated from the face of the earth and future generations will never suffer from its effects.

The US Food and Drug Administration has approved tavapadon, a once-daily oral medicine for adults with Parkinson’s disease. This has added a new option to Parkinson's treatment strategy that has long relied on drugs that mimic the brain’s dopamine supply. The drug will be sold in the US under the brand name Juvmo.

Tavapadon is different from traditional dopamine agonists because it selectively targets D1 and D5 dopamine receptors. It has been studied both as an early treatment and alongside levodopa in people with more advanced Parkinson’s disease and motor fluctuations.

Parkinson’s Disease & Dopamine

Parkinson’s disease is a progressive neurological disorder in which dopamine-producing nerve cells in a region of the brain called the substantia nigra disappear gradually.

Dopamine is essential for controlling movement. As its levels fall, people can develop symptoms like tremor, stiffness, slowness of movement and problems with balance.

This is why many Parkinson’s treatments entail increasing dopamine levels or mimicking its effects in the brain.

How Does Tavapadon Work?

Also read: Parkinson’s Is Rising Across US, But Not Equally: Why Are Some States Seeing More Cases Than Others?

Tavapadon is a selective D1/D5 partial dopamine agonist. It means that it does not simply increase the amount of dopamine in the brain. Instead, it binds to particular dopamine receptors and partially activates them, essentially helping reproduce some of dopamine’s signalling effects.

Most currently available dopamine agonists target D2/D3 receptors. Tavapadon’s D1/D5 is therefore one of its distinguishing characteristics. Researchers have been investigating whether this drug can can help provide motor symptom relief while avoiding some adverse effects linked with dopamine receptor activation.

The FDA’s approval was supported by the phase 3 TEMPO clinical programme. In TEMPO-1, which involved 529 people with early Parkinson’s disease, both 5 mg and 15 mg daily doses of tavapadon significantly improved motor function compared to placebo after 26 weeks.

The drug has also been studied in people already taking levodopa who experience motor fluctuations, a common problem with progressive Parkinson’s. In the TEMPO-3 trial involving 507 participants, adding tavapadon to levodopa increased daily 'on' time without troublesome dyskinesia compared to placebo.

As Parkinson’s disease progresses, some people taking levodopa experience periods when the medicine is working well and movement improves. This is called 'on' time. When the medication’s effect wears off and Parkinson’s symptoms return, it is called 'off' time.

Treatment aims to increase 'on' time while limiting troublesome involuntary movements, known as dyskinesia.

Side Effects Of Tavapadon?

Tavapadon was generally tolerated in the clinical trials, but it is not free of side effects. In the TEMPO-1 trial, the most commonly reported adverse events were:

• Nausea
• Headache
• Dizziness

The FDA’s approval follows data showing improvement in Parkinson’s symptoms, but longer-term safety remains an important factor that needs more investigation.

Dopamine agonists can also be associated with sleepiness, low blood pressure on standing, hallucinations and impulse-control disorders. These issues remain relevant when doctors consider where tavapadon fits into an individual’s treatment plan.

Tavapadon treats the symptoms of Parkinson’s disease. It does not restore the dopamine-producing nerve cells that have been lost or stop the neurodegenerative process.

The World Health Organization (WHO) today announced its recommendations for the viral composition of influenza (or “flu”) vaccines for the 2027 southern hemisphere influenza season.

The announcement comes as US states can now order free COVID-19 vaccines for eligible children through the federal Vaccines for Children (VFC) program, following a nearly month-long delay.

Why WHO Is Updating Flu Vaccine Strains

Seasonal influenza causes substantial illness and hospitalizations each year. Because influenza viruses continually evolve, vaccine compositions need to be regularly updated.

WHO recommendations guide national vaccine regulators and manufacturers in developing and licensing vaccines for the following flu season.

"For nearly 75 years, the WHO Global Influenza Surveillance and Response System has demonstrated the power of global solidarity in public health," said Dr Maria Van Kerkhove, WHO's Director for Epidemic and Pandemic Management.

"The commitment of countries and laboratories to share data, viruses and expertise enables WHO to make timely vaccine recommendations, strengthening our collective ability to detect and respond to emerging influenza threats. This is global public health collaboration at its best," she added.

Also read: Fall Vaccines 2026: US Doctors Issue COVID, Flu And RSV Jab Guidance

What Are The 2027 Flu Vaccine Strains?

From February through August 2026, influenza A(H1N1)pdm09, A(H3N2) and influenza B viruses circulated across regions. Influenza A viruses predominated in most regions, while influenza B dominated in Northern and Western Africa, North America and Eastern Asia.

WHO recommends the following strains for the 2027 southern hemisphere influenza season:

Egg-based vaccines

• A/Missouri/11/2025 (H1N1)pdm09-like virus
• A/Darwin/1454/2025 (H3N2)-like virus
• B/Tokyo/EIS13-175/2025 (B/Victoria lineage)-like virus

Cell culture-, recombinant protein- or nucleic acid-based vaccines

• A/Missouri/11/2025 (H1N1)pdm09-like virus
• A/Darwin/1415/2025 (H3N2)-like virus
• B/Pennsylvania/14/2025 (B/Victoria lineage)-like virus

WHO also reviewed influenza viruses circulating in animals because of their potential to cause human infections and pandemics.

Free COVID Vaccines For US Children

Read More: COVID-19 Rising In 35 US States: Sore Throat, Diarrhea Among Key Symptoms

The VFC program provides free immunizations to more than half of U.S. children, including those covered by Medicaid, uninsured or underinsured children, and Native Americans and Alaska Natives.

The FDA approved the updated COVID-19 vaccines on August 27, but access through the VFC program was delayed.

Although overall COVID-19 hospitalization rates remain low, they have been rising since mid-June. According to the CDC, hospitalization rates are highest among babies younger than 1 year old and adults aged 65 and older.

States Can Now Order COVID Vaccines

Public health officials from multiple states confirmed that they can now order the free vaccines.

South Carolina’s health department “was alerted yesterday afternoon by the CDC that COVID vaccines would be available for order today,” Casey White, a department spokeswoman, told CIDRAP News.

“Announcements will be shared with VFC providers and health departments to communicate the opening of ordering for all respiratory immunizations.”

WHO said it will issue its recommendation for vaccines for the 2027–28 northern hemisphere influenza season in February 2027.

Nearly 20 prescriptions for life-ending medication were reportedly issued in New York during the first month of its Medical Aid in Dying (MAiD) law, according to a Columbia University bioethics expert.

However, state health officials have not yet released data showing how many patients actually used the medication.

New York’s Medical Aid in Dying Act took effect on August 5, making it the 14th US state to legalize medical aid in dying.

David Hoffman, assistant professor of professional practice in bioethics at Columbia University, told The New York Post that conversations with doctors, hospitals and organizations indicated that about 20 prescriptions had been issued since the law took effect.

“The state will have the data on a rolling basis. It’s an after-the-fact analysis,” Hoffman told The Post.

The New York State Department of Health has yet to release precise figures on the program’s use.

New York Assisted Suicide Law: Why Is It Controversial?

Read More: Supreme Court Allows 1st Passive Euthanasia For Man In Vegetative State For 13 Years

The lack of publicly available data has drawn criticism from lawmakers who opposed the law. Upstate Republican Assemblyman Andrew Molitor told The New York Sun that New Yorkers should know how many people have requested and used medical aid in dying.

He said information should include patients’ socioeconomic status, insurance coverage, terminal condition, when prescriptions were filled and where the medication was administered.

Western New York Republican state Sen. George Borrello also criticized the wait for the state’s first annual report.

Critics have additionally raised concerns about whether the law could eventually be expanded. Borrello pointed to Canada, where medical assistance in dying was legalized in 2016.

Medical aid in dying remains controversial because it raises ethical, religious and moral questions. Critics warn about the potential coercion of vulnerable patients, while supporters emphasize personal autonomy and relief from prolonged, incurable suffering.

Medical aid in dying generally involves a patient voluntarily taking lethal medication prescribed by a doctor. Euthanasia, by contrast, involves a healthcare professional administering the lethal medication at the patient’s request.

Who Can Qualify For Medical Aid In Dying In New York?

Under New York’s law, patients must:

• Be at least 18 years old.

• Be a New York resident.

• Have a terminal illness with six months or less to live.

• Have the capacity to make an informed healthcare decision.

• Be physically capable of self-administering the medication.

• Receive approval from two physicians.

• Undergo a psychiatric evaluation when required to assess decision-making capacity.

• Make an oral request and provide an audio or video recording of that request.

The law also requires a five-day waiting period between obtaining and dispensing the prescription.

Medical aid in dying requires the patient to take the prescribed medication themselves. This differs from euthanasia, in which a healthcare professional administers the life-ending medication.

How Will New York Track The Program?

Also read: Can Right To Die Be Practiced By Non-Terminally Ill Patients?

The law requires the state health commissioner to submit an annual report to the Legislature detailing the program’s use.

Hoffman noted that doctors report when medication is prescribed, but the state may not immediately know whether a patient ultimately takes it.

A New York State Department of Health spokesperson told The Post that the department will publish an annual report with utilization data as required by law.

Health Commissioner Dr. James McDonald said end-of-life decisions are “deeply personal” and should be made individually in consultation with patients, doctors, families and loved ones. The department has also issued guidance and proposed regulations intended to prevent misuse or inappropriate application of the law.

Assisted-Dying Laws In Other Countries

The debate over medical aid in dying extends beyond New York and the US.

France’s National Assembly recently gave final approval to a bill that would allow certain adults with incurable illnesses to receive lethal medication, following years of debate over end-of-life care.

Assisted-dying legislation is also being debated in the UK, where a bill covering England and Wales is returning to Parliament.